• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s lead clinical late stage programs address hospital and healthcare associated infections.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A leading pure play vaccine company.

2015 Annual Business Report

— August 31, 2016

Valneva Reports Strong Revenue Growth and Positive EBITDA in H1 Confirming the Company’s Trend towards EBITDA Break-even

Read more

— Stock information


— July 25, 2016
Valneva Announces Successful Completion of Phase II for C. Diff Vaccine Candidate

Read more

— Financial Calendar

November 9, 2016
Q3 2016 Results

See all dates


learn more
play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

– Upcoming conferences and fairs

Jefferies London Healthcare Conference
London UK
November 16-17, 2016

Please update your browser...